Janssen

Leading partner

Information

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. 

We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/emea/. Follow us at @JanssenEMEA

Social media

Contact details

https://www.janssen.com/emea/

Videos

Panel discussion - Is Europe ready for the next crisis?

Panel discussion - Is Europe ready for the next crisis?

Chris Fearne · Ministry for Health, Malta
Bart van Zijll Langhout, · Janssen
Moderator: Sarah Wheaton · POLITICO
Annabel Seebohm · Standing Committee of European Doctors (CPME)
Wolfgang Philipp · European Commission
Spotlight discussion - Tackling the two-speed Europe in access to care

Spotlight discussion - Tackling the two-speed Europe in access to care

Stanimir Hasardzhiev · Patient Access Partnership
Martin Price · Janssen
Cristian Silviu Bușoi · European Parliament
Mark Lawler · Queen's University Belfast
Moderator: Carlo Martuscelli · POLITICO

Documents & Links

The Dawning of a Well-Care EraKris Sterkens, Company Group Chairman of Janssen EMEA, explains how the sun is setting on “sick-care” and why now, it’s time for the dawning of a Well-Care era
Why a new innovation pact can make health systems resilient and sustainableAnouk De Vroey, Government Affairs & Policy team lead at Janssen pharmaceuticals, explains how a new health innovation pact can improve European health systems
Economist Report Reinforces the Need to Rethink HTA Methods in EuropeNew Economist Intelligence Unit report reinforces the need to rethink health technology assessment methods in Europe, by Martin Price
Breaking DepressionBreaking Depression aims to raise awareness of the challenges of living with different types of depression, including major depressive disorder (MDD).
Attracting Life Science Investments in EuropeThe Life Sciences Investment Attractiveness Report compares the attractiveness of countries in terms of life science investments
HTAiC NarrativeIs now the time to think differently about using overall survival rates to assess innovative cancer medicines?
Accelerating Access to Innovative Cancer TherapiesJanssen’s key recommendations for accelerating access to innovative cancer therapies
The Economist Intelligence Unit – Assessing InnovationHow Health Technology Assessment can adapt to improve the evaluation of novel cancer therapies in Europe

Log in